[ 177 Lu]Lu-DOTA-TATE versus Temozolomide-Capecitabine in Gastroenteropancreatic Neuroendocrine Tumours: A Real-World Retrospective Cohort Study (EANM 2026) - Sep 29, 2026 - Abstract #OP-266; Pres time: Oct 18, 2026; 04:45 PM - 06:15 PM; Location: Hall G1; "In this real-world analysis, PRRT with [177Lu]Lu-DOTA-TATE demonstrated a superior OS relative to TEMCAP in patients with advanced GEP-NETs, regardless of tumour location. These results reinforce the role of PRRT as an effective treatment strategy and underscore the importance of prospective, randomized trials to identify optimal treatment strategies across patient subgroups and to better delineate drivers of treatment response."
Real-world • Real-world evidence • Retrospective data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor
|
|
M. Kappenstein 1; N. Ninosu 2; A. Hamm 3; K. Klimek 4; V. Koehler 5; C. Koch 5; J. Bojunga 5; R. Werner 6; N. von Bubnoff 7; D. Groener 1
|